Report ID: SQSG35I2019
Report ID:
SQSG35I2019 |
Region:
Global |
Published Date: December, 2024
Pages:
242
|
Tables:
92 |
Figures:
76
Based on the region, the European region currently dominates the global allergy immunotherapy market with respect to market share, and it is projected that it will continue to hold a sizable share of the market throughout the forecast period. Due to high awareness, increased financing for research and grants, medical reimbursement rules, the rise in the population with allergies, and other factors, Europe was reported to hold the largest share of the worldwide allergy immunotherapy market. According to the European Academy of Allergy and Clinical Immunology (EAACI), 20 percent of the population in the area currently experiences chronic food allergies, which affect over 150 million people.
Asthma and allergic rhinitis are the most prevalent allergens, affecting 100 million and 70 million individuals, respectively. Furthermore, according to the organization, by 2025, 50 percent of the people in Europe would suffer from allergies, opening up a huge market for allergy immunotherapy.
The prevalence of allergies in Europe is also becoming a significant economic burden as a result of the ensuing productivity losses in European countries. In response to these issues, European governments and organizations, such as EAACI, are trying to increase public awareness and urge for better medical education and treatments, which will help the market in the area flourish.
Our industry expert will work with you to provide you with customized data in a short amount of time.
REQUEST FREE CUSTOMIZATIONWant to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Report ID: SQSG35I2019